The global artificial lung market size was valued at USD 2.63 billion in 2025 and is projected to grow from USD 2.91 billion in 2026 to USD 6.52 billion by 2034, registering a CAGR of 10.61% during the forecast period from 2026 to 2034. North America dominated the artificial lung market with a market share of 39.2% in 2025.
An artificial lung is a medical device designed to temporarily perform the gas exchange function of the lungs by adding oxygen to the blood and removing carbon dioxide. It is commonly used in critical care settings, particularly during extracorporeal membrane oxygenation (ECMO) and certain cardiac or pulmonary surgeries. Artificial lungs provide life-saving respiratory support for patients with severe heart or lung failure while their organs recover or until transplantation is possible.
Download a Free Sample To learn more about this report,
Miniaturization and Portability of Artificial Lung Systems
The need for greater patient mobility and less dependence on large bedside equipment is encouraging the development of compact artificial lung systems. This transition is shifting respiratory-support technology toward smaller, wearable, and low-resistance devices that can support ambulation and potentially extend care beyond conventional ICU settings. A wearable extracorporeal CO₂-removal prototype demonstrated automatic adjustment to changing metabolic conditions within 1 minute during in-vitro testing, highlighting progress toward portable respiratory-support platforms.
Bioengineered Gas-Exchange Membranes Gaining Importance
Limitations associated with blood compatibility and long-term use of conventional synthetic oxygenator membranes are directing research toward biologically integrated gas-exchange surfaces. This transition combines engineered membranes with endothelial or other biological cells to improve gas transfer while reducing adverse blood-material interactions, supporting longer-duration artificial lung concepts. A 2026 study developed a collagen-based biological membrane only 18.8 ± 3.6 μm thick that achieved about 75% of the gas transfer of a 51 μm implantable silicone sheet, demonstrating progress toward biofabricated support lungs.
Higher Incidence of Severe Respiratory Failure and Shortage of Donor Lungs for Transplantation Drive Market
A higher burden of acute respiratory failure, including severe ARDS and complications from pneumonia or sepsis, expands the patient pool requiring advanced gas-exchange support. Greater use of extracorporeal respiratory support in intensive care increases demand for artificial lung systems when conventional ventilation is insufficient. Hospitals with ECMO programs create a steady clinical base for artificial lung technologies, especially in patients needing temporary support during recovery. Broader critical-care adoption therefore strengthens demand for artificial lung devices while encouraging manufacturers to expand system availability and clinical support capabilities.
Limited availability of suitable donor lungs creates a persistent gap between transplant demand and organ supply. Longer waiting periods increase the need for artificial lung systems that can support critically ill patients until transplantation becomes possible. Bridge-to-transplant applications already use extracorporeal oxygenation in selected patients to maintain respiratory function while they remain on transplant waiting lists. Persistent donor shortages therefore support demand for longer-duration artificial lung technologies and encourage suppliers to develop systems suited for extended clinical use.
High Cost of Artificial Lung Systems and Treatment and Limited Clinical Evidence for Long-Term Artificial Lung Use Restrain Market Expansion
High costs associated with artificial lung devices, extracorporeal equipment, disposables, monitoring, and specialized clinical teams increase the financial burden on hospitals and patients. Limited healthcare budgets can restrict installation and treatment availability, particularly in smaller hospitals and developing regions. This cost pressure slows wider adoption and limits overall market expansion.
Limited long-term clinical data creates uncertainty around the safety, durability, and effectiveness of emerging artificial lung technologies. Hospitals and clinicians may remain cautious about adopting newer systems until stronger evidence supports extended use and patient outcomes. This evidence gap delays commercialization and restricts broader clinical adoption.
Development of Wearable and Ambulatory Artificial Lung Platforms and Expansion of Artificial Lung Use in Bridge-to-Recovery and Bridge-to-Transplant Care Offers Growth Opportunities
Medical device manufacturers, transplant centers, and critical-care providers can benefit from respiratory support systems that allow greater patient mobility. Wearable platforms can create revenue through advanced device sales, disposable components, monitoring systems, and long-term clinical support services. Portable systems such as the FDA-approved Breethe OXY-1 and research programs around ambulatory artificial lungs show commercial and clinical interest in this area.
Hospitals, transplant programs, ECMO centers, and artificial lung manufacturers can benefit from broader use of artificial lungs during recovery or while patients await transplantation. Bridge therapy can generate revenue from equipment placement, oxygenators, replacement circuits, clinical support, and extended-use service contracts. Clinical work with portable ECMO and ambulatory artificial-lung systems already supports their role in maintaining patients during these care pathways.
Blood Compatibility and Clotting Management Complicate Device Development and Supply Constraints for Critical Oxygenator Components
Blood contact with artificial lung membranes can trigger clot formation, while anticoagulation used to control this risk can contribute to bleeding complications. These competing risks make membrane design, clinical management, and product development more complex and can slow wider adoption of artificial lung systems. Recent ECMO evidence continues to identify bleeding and thrombosis among the most important complications of extracorporeal support.
Artificial lung manufacturers depend on specialized oxygenators, membranes, pumps, sensors, and other medical-grade components that require strict quality control and reliable supply. Component shortages can limit production volumes, disrupt hospital availability, and make it difficult for companies to expand commercially. A real-life example is the U.S. FDA's June 2026 update extending shortages of extracorporeal-circulation oxygenator devices into the first quarter of 2027.
The extracorporeal membrane oxygenation (ECMO) systems segment dominated the artificial lung market with a market share of 40.8% in 2025, supported by its widespread use for temporary cardiopulmonary support in patients with severe respiratory failure. Established use across intensive-care units and the availability of trained clinical teams continue to support the segment’s leading position.
The paracorporeal artificial lungs segment is expected to grow at a CAGR of 8.1% during the forecast period 2026–2034, supported by their ability to provide external respiratory assistance while offering greater flexibility in patient management. Intracorporeal artificial lungs are supported by ongoing development of internally positioned systems designed for extended respiratory support. Membrane oxygenators remain important in extracorporeal procedures by enabling oxygen and carbon dioxide exchange, while portable artificial lungs benefit from efforts to improve patient mobility and reduce dependence on large bedside equipment.
Request Customizationto receive a tailored report.
The bridge-to-transplantation segment dominated the artificial lung market with a market share of 30.6% in 2025, supported by the use of artificial lung systems to maintain patients with advanced respiratory failure while they wait for suitable donor lungs. The shortage of donor organs continues to strengthen the role of temporary respiratory support within transplant programs.
The bridge-to-recovery segment is expected to grow at a CAGR of 8.3% during the forecast period 2026–2034, supported by the use of temporary respiratory assistance while patients recover from severe lung injury or acute respiratory failure. ECMO-assisted ventilation remains important in critical care when conventional mechanical ventilation does not provide sufficient respiratory support. Pulmonary rehabilitation supports selected patients who require respiratory assistance while maintaining physical activity, while long-term support for chronic lung diseases addresses the need for prolonged respiratory care.
The tertiary care hospitals segment dominated the artificial lung market with a market share of 48.7% in 2025, supported by the concentration of intensive-care units, ECMO programs, advanced respiratory equipment, and specialized clinical teams. Their ability to manage critically ill patients and provide continuous monitoring strengthens their role in artificial lung procedures.
The transplant centers segment is expected to grow at a CAGR of 9.1% during the forecast period 2026–2034, supported by the use of artificial lung systems for patients awaiting lung transplantation and requiring advanced respiratory support. Research institutions and clinical trial sites contribute through the development and evaluation of wearable artificial lungs, advanced gas-exchange technologies, and other next-generation systems. Specialty respiratory clinics support patient evaluation, respiratory management, and follow-up care for individuals requiring advanced lung-support therapies.
Speak to an Analystto discuss market opportunities.
North America accounted for the largest share of the artificial lung market at 39.2% in 2025. The region's strong position reflects well-developed critical-care facilities, broad use of advanced respiratory support technologies, and a strong base of medical device companies.
The U.S. artificial lung market is supported by demographic aging, as the U.S. Census Bureau projects the share of Americans aged 65 and older to increase from 18.9% in 2025 to 23.4% by 2060, potentially enlarging the pool of patients who may require high-acuity respiratory intervention. The Canada artificial lung market is similarly influenced by population aging, with the share of people aged 65 and older projected to rise from 19.5% in 2025 to between 22.6% and 32.5% by 2075, which may strengthen long-term utilization of complex respiratory treatment and life-support systems.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe is projected to be the fastest-growing region in the artificial lung market, registering a CAGR of 7.8% during the forecast period. The region’s growth is supported by expanding ECMO capabilities, continued investment in critical-care infrastructure, and wider clinical adoption of advanced cardiopulmonary support technologies. The U.K. artificial lung market is influenced by demographic aging, as the Office for National Statistics projects the population aged 85 years and older to increase from 1.75 million in 2024 to 3.6 million by 2049, raising the potential volume of very elderly patients requiring intensive respiratory management.
The Germany artificial lung market is supported by a widening elderly patient base, with the Federal Statistical Office projecting the population aged 80 years and older to rise from around 6 million through 2030 to between 8.5 million and 9.8 million by 2050, which may increase pressure on hospitals to strengthen life-support capacity and intensive-care readiness. The France artificial lung market is shaped by long-term population aging, as INSEE projects the share of people aged 75 years and older to increase from 12.3% in 2030 to 16.5% by 2050 and 19.3% by 2070, supporting sustained need for specialized cardiopulmonary care across an expanding older population.
The Asia Pacific artificial lung market accounted for a 22.4% share in 2025 and is projected to expand at a CAGR of 10.6% during the forecast period. The regional market is supported by improvements in critical-care capacity, wider access to advanced respiratory support technologies, and continued development of specialized healthcare facilities. The Japan artificial lung market is influenced by demographic aging, as the National Institute of Population and Social Security Research projects the share of people aged 65 and older to increase from 28.6% in 2020 to 36.3% by 2045 and 38.7% by 2070, creating a larger long-term elderly population that may require sophisticated respiratory treatment.
The China artificial lung market is shaped by increasing healthcare pressure from an aging population, with the National Health Commission projecting around 420 million people aged 60 and older by 2035, accounting for more than 30% of the population and placing additional pressure on hospital capacity, intensive-care resources, and advanced respiratory services. The South Korea artificial lung market is supported by a rapidly aging population, as Statistics Korea projects people aged 65 and older to exceed 30% of the population by 2036 and 40% by 2050, which may increase the need for specialized cardiopulmonary care and high-dependency treatment services.
The artificial lung market is relatively concentrated, with a limited number of established medical device companies, specialized extracorporeal life-support manufacturers, research institutions, and technology-focused startups active in the space. Established players compete mainly on clinical reliability, regulatory approvals, gas-exchange efficiency, product safety, and strong relationships with hospitals and transplant centers. Medtronic, Getinge AB, Terumo Corporation, LivaNova PLC, and Fresenius Medical Care are among the leading players in the artificial lung market, collectively accounting for approximately 40–45% of the global market share.
Emerging players focus more on device miniaturization, portability, advanced membrane technologies, and differentiated artificial-lung designs that improve mobility and long-term support potential. Competition across the artificial lung market continues to depend heavily on clinical validation, technological performance, regulatory progress, and the ability to translate experimental systems into commercially scalable respiratory-support solutions.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Aerosol Delivery Devices Market Size, Share, Growth, 2034
Artificial Cornea and Corneal Implant Market Size, Share, 2034
Active Wheelchair Market Size, Share, Growth, Forecast, 2034
Alpha Emitter Market Size, Share, Growth, Analysis, Report, 2034
Advanced Wound Care Market Size, Share, Growth, Analysis, 2034
Acute Wound Care Market Size, Share, Growth, Forecast, 2034
We are featured on:
sales@straitsresearch.com